Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Ewa, Janczewska"'
Publikováno v:
Metabolites, Vol 13, Iss 12, p 1174 (2023)
Interconnections between hypothyroidism and metabolic disturbances manifesting in the liver and body composition have not yet been comprehensively analyzed in the context of lifestyle. This study aimed to assess the selected lifestyle factors and qua
Externí odkaz:
https://doaj.org/article/6fa606346d6a42e58589aba2f8b4c239
Publikováno v:
Metabolites, Vol 13, Iss 10, p 1033 (2023)
The lifestyle causes of metabolic disorders in patients with hypothyroidism should be investigated. We aimed to assess the lifestyle and quality of life of women diagnosed with hypothyroidism and search for the presence of differences between the lif
Externí odkaz:
https://doaj.org/article/9ca16414b5114582bc9c7fa1059e1b91
Autor:
Laura L. Hammitt, Dean Quinn, Ewa Janczewska, Francisco J. Pasquel, Richard Tytus, K. Rajender Reddy, Katia Abarca, Ilsiyar M. Khaertynova, Ron Dagan, Rachel Dawson, Jennifer McCauley, Tulin Shekar, Wei Fu, Alison Pedley, Tina Sterling, Gretchen Tamms, Luwy Musey, Ulrike K. Buchwald
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023)
Immunocompetent adults with certain medical and behavioral factors are at increased risk of pneumococcal disease. In some countries, sequential vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polys
Externí odkaz:
https://doaj.org/article/f875d2655e614b2e8e50c8bd1322293d
Autor:
Christoph Schramm, Heiner Wedemeyer, Andrew Mason, Gideon M. Hirschfield, Cynthia Levy, Kris V. Kowdley, Piotr Milkiewicz, Ewa Janczewska, Elena Sergeevna Malova, Johanne Sanni, Phillip Koo, Jin Chen, Subhajit Choudhury, Lloyd B. Klickstein, Michael K. Badman, David Jones
Publikováno v:
JHEP Reports, Vol 4, Iss 11, Pp 100544- (2022)
Background & Aims: The safety, tolerability, and efficacy of the non-bile acid farnesoid X receptor agonist tropifexor were evaluated in a phase II, double-blind, placebo-controlled study as potential second-line therapy for patients with primary bil
Externí odkaz:
https://doaj.org/article/3923e32517ec458db31731c6b79c2204
Autor:
Olga Tronina, Michał Brzdęk, Dorota Zarębska-Michaluk, Dorota Dybowska, Beata Lorenc, Ewa Janczewska, Włodzimierz Mazur, Anna Parfieniuk-Kowerda, Anna Piekarska, Rafał Krygier, Jakub Klapaczyński, Hanna Berak, Jerzy Jaroszewicz, Aleksander Garlicki, Krzysztof Tomasiewicz, Jolanta Citko, Robert Flisiak
Publikováno v:
Viruses, Vol 15, Iss 3, p 677 (2023)
Direct-acting antivirals (DAA) regimens have provided hope for eliminating hepatitis C virus (HCV) infection. Patients following ineffective therapy with DAA, especially those previously treated with inhibitors of non-structural protein 5A (NS5A), re
Externí odkaz:
https://doaj.org/article/f76918a6d9b84ca3a68b0e5269e09f90
Autor:
Harry L A Janssen, Jinlin Hou, Tarik Asselah, Henry L Y Chan, Fabien Zoulim, Yasuhito Tanaka, Ewa Janczewska, Ronald G Nahass, Stefan Bourgeois, Maria Buti, Pietro Lampertico, Oliver Lenz, Thierry Verbinnen, Joris Vandenbossche, Willem Talloen, Ronald Kalmeijer, Maria Beumont, Michael Biermer, Umesh Shukla
Publikováno v:
Gut. BMJ Publishing Group
Scientia
Scientia
ObjectiveWe present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier:NCT03361956).Design232 patients with chronic hepatitis B (CHB) not currently treated at study start (NCT) at study start or virologically suppress
Autor:
Dorota Zarębska-Michaluk, Anna Piekarska, Jerzy Jaroszewicz, Jakub Klapaczyński, Marek Sitko, Magdalena Tudrujek-Zdunek, Krzysztof Tomasiewicz, Teresa Belica-Wdowik, Paweł Pabjan, Beata Lorenc, Agnieszka Czauż-Andrzejuk, Olga Tronina, Rafał Krygier, Witold Dobracki, Iwona Buczyńska, Krzysztof A. Simon, Dorota Dybowska, Waldemar Halota, Małgorzata Pawłowska, Jolanta Citko, Łukasz Laurans, Włodzimierz Mazur, Ewa Janczewska, Łukasz Socha, Zbigniew Deroń, Hanna Berak, Robert Flisiak
Publikováno v:
Archives of Medical Science, Vol 18, Iss 6, Pp 1460-1466 (2019)
Introduction Non-cirrhotic treatment-naive hepatitis C patients infected with genotype 1 can be treated with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, but in practice this regimen is frequently extended up to 12 weeks at least in part due to insuf
Externí odkaz:
https://doaj.org/article/98c74331a41c48fab58d3002fa6f0ffa
Publikováno v:
World Journal of Hepatology. 15:641-648
Autor:
Ewa Janczewska, Dorota Zarębska-Michaluk, Hanna Berak, Anna Piekarska, Andrzej Gietka, Dorota Dybowska, Włodzimierz Mazur, Teresa Belica-Wdowik, Witold Dobracki, Magdalena Tudrujek-Zdunek, Zbigniew Deroń, Iwona Buczyńska, Marek Sitko, Agnieszka Czauż-Andrzejuk, Beata Lorenc, Jolanta Białkowska-Warzecha, Jolanta Citko, Łukasz Laurans, Jerzy Jaroszewicz, Łukasz Socha, Olga Tronina, Brygida Adamek, Andrzej Horban, Waldemar Halota, Barbara Baka-Ćwierz, Krzysztof Tomasiewicz, Krzysztof Simon, Aleksander Garlicki, Marta Wawrzynowicz-Syczewska, Robert Flisiak
Publikováno v:
BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background According to the EASL and AASLD guidelines, the recommended treatment for patients who failed to achieve a sustained virologic response (SVR) on prior interferon-based triple therapy with protease inhibitors (PI), is a combination
Externí odkaz:
https://doaj.org/article/f74922258b364284bf1043b0ac680f8f
Autor:
Flisiak, Monika Pazgan-Simon, Jerzy Jaroszewicz, Krzysztof Simon, Beata Lorenc, Marek Sitko, Dorota Zarębska-Michaluk, Dorota Dybowska, Magdalena Tudrujek-Zdunek, Hanna Berak, Włodzimierz Mazur, Jakub Klapaczyński, Ewa Janczewska, Anna Parfieniuk-Kowerda, Robert
Publikováno v:
Journal of Personalized Medicine; Volume 13; Issue 7; Pages: 1111
Introduction: In Poland, active HCV infection affects between 0.4 and 0.5% of the population, i.e., about 150,000 people, while the number of patients with epilepsy is estimated to be 350,000–400,000. Currently available antiviral therapies show li